News

Exposure to chemical substances used in leather tanning may have been the cause of a rare case of subcutaneous (under-the-skin) sarcoidosis around a man’s left eye and mouth, a recent case report suggests. The report, “Occupational exposure as a presumable cause of subcutaneous sarcoidosis in a tannery…

The Foundation for Sarcoidosis Research (FSR) has invested $1 million in its new Clinical and Research Fellowship Program. It also gave travel awards to the first authors of the top four abstracts submitted for presentation at the annual conference of the Americas Association of Sarcoidosis and Other Granulomatous Disorders…

The Foundation for Sarcoidosis Research is calling for everyone to participate this month of April in a campaign to celebrate those living with sarcoidosis. This year’s campaign, #SarcoidStories, is an effort to raise awareness among the general public about the daily challenges and joys in the lives of…

A little-known government entity within the National Institutes of Health (NIH) is helping to lead U.S. efforts to speed up the development of therapies for some 7,000 rare diseases. The Office of Rare Diseases Research (ORDR), headquartered in Bethesda, Maryland, was established in 1993 within the NIH Office of the…

The American Lung Association, CHEST Foundation and the Foundation for Sarcoidosis Research (FSR) teamed up to bring greater awareness to sarcoidosis and encourage patients to be more proactive in their treatment programs. The joint effort,…

A recent study found that migraines are at least as common in patients with sarcoidosis as they are in the general public, and they affect women more than men. The study’s authors highlighted the need for better recognition and targeted treatment of migraine in people with sarcoidosis. The study, “…

A wearable cardioverter-defibrillator can prevent sudden death in patients with cardiac sarcoidosis, new research demonstrates. A study found the device was capable of restoring heart rhythm in all patients who experienced abnormal and potentially life-threatening heartbeats. Results were reported in the study,…

Bardoxolone methyl, an investigational therapy developed by Reata Pharmaceuticals, was shown to significantly improve the exercise capacity of patients with pulmonary hypertension (PH) associated with sarcoidosis in a Phase 2 clinical trial. Bardoxolone is an experimental, oral molecule that promotes the resolution of inflammation by targeting an important mediator…

A project studying the possible link between sarcoidosis and lung microbes received a four-year, $2.7 million grant from the National Institutes of Health (NIH). The research will be conducted at the University of Illinois at Chicago and may help predict disease prognosis. Sarcoidosis is an inflammatory disorder that…

Genetic sequencing and the speed with which it can help diagnose a child’s disease — in addition to revealing the genes that cause at least half of the 7,000 rare diseases currently known — was the focus of a discussion by three top New York geneticists. The Feb. 28 conference,…